The Role of Ultrasound in COVID-19

Study Overview
=================
Brief Summary
-----------------
The study is a prospective clinical cohort study of consecutive patients hospitalized at all hospitals of greater Copenhagen with a laboratory confirmed diagnosis of COVID-19. The investigators aim to examine if echocardiography - both conventional and advanced - can be used to predict which patients will develop acute respiratory distress syndrome (ARDS) or other short-term acute complications, especially focusing on cardiovascular outcomes. In addition, using a novel technique of lung ultrasound (LUS), The investigators aim to analyze specific LUS-findings, and associate them with short-term prognosis and development of ARDS and long-term cardiovascular morbidity and mortality. In all patients included, The investigators aim to examine long-term complications at timepoints: 2, 5 and 10 years of follow-up and examine if echocardiography - alone and in combination with biomarkers - can be used to detect early signs of cardiac complications and predict long-term risk of cardiovascular morbidity and mortality following COVID-19 infection

Official Title
-----------------
The ECHOVID-19 Study - A Prospective Cohort Study Investigating the Acute Effect of COVID-19 on the Heart and Lung by Ultrasound

Conditions
-----------------
COVID-19

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients hospitalized at hospitals of greater Copenhagen area and Zealand with a laboratory confirmed diagnosis of COVID-19 > 18 years of age. Exclusion Criteria: Persons not able to cooperate Persons unable to understand and sign informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| In-hospital mortality during hospitalization and a confirmed COVID-19 diagnosis |  | 2.5 months | 
| Incident ARDS (Adult Respiratory Distress Syndrome) and intensive care unit admission during hospitalization and a confirmed COVID-19 diagnosis |  | 2.5 months | 
| Incident hypoxic respiratory failure during hospitalization and a confirmed COVID-19 diagnosis |  | 2.5 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incident pulmonary embolism during hospitalization and a confirmed COVID-19 diagnosis |  | 2.5 months | 
| Incident cardiac arrest during hospitalization and a confirmed COVID-19 diagnosis |  | 2.5 months | 
| Death from any cause after hospital admission with a confirmed COVID-19 diagnosis at follow-up |  | 2.5 months to 10 years | 
| Incident stroke after hospital admission with a confirmed COVID-19 diagnosis at follow-up |  | 2.5 months to 10 years | 
| Incident heart failure after hospital admission with a confirmed COVID-19 diagnosis at follow-up |  | 2.5 months to 10 years | 
| Incident myocardial infarction after hospital admission with a confirmed COVID-19 diagnosis at follow-up |  | 2.5 months to 10 years |